BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231004T130000
DTEND;TZID=America/New_York:20231004T140000
DTSTAMP:20260406T063156
CREATED:20230919T202042Z
LAST-MODIFIED:20230919T202042Z
UID:45601-1696424400-1696428000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview from Novo Nordisk - An injectable\, extended half-life recombinant\, glycopegylated factor VIII concentrate for Hemophilia A
DESCRIPTION:Date: Wednesday\, October 4\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nAn injectable\, extended half-life recombinant\, glycopegylated factor VIII concentrate for Hemophilia A \nOBJECTIVE:\nProvide a clinical overview of Esperoct that supports prophylactic\, on-demand and perioperative management indications in adults and children. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nParin Chikani\, PharmD\, MBA \nMedical Account Director\, Novo Nordisk Inc \nParin Chikani\, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago\, College of Pharmacy and his MBA from Kellstadt Graduate School of Business.  Before joining Novo Nordisk\, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business.  At Novo Nordisk\, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-from-novo-nordisk-on-esperoct/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231008
DTEND;VALUE=DATE:20231011
DTSTAMP:20260406T063156
CREATED:20230105T220827Z
LAST-MODIFIED:20230615T184307Z
UID:39898-1696723200-1696982399@hemoalliance.org
SUMMARY:🟥 Member Event : Fall Members Meeting
DESCRIPTION:Venue: The St. Anthony Hotel\nLocation: San Antonio\, Texas \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568. \n\nDRAFT AGENDA: \n\nOct. 8th – Welcome Reception @ 6pm\nOct. 9th – Breakfast @ 7:30am; Meeeting:  8:30am – 5:00pm; Group Dinner @ 6:30 pm\nOct. 10th – Breakfast @ 7:30am; Meeeting:  8:30am – 3:30pm
URL:https://hemoalliance.org/alliance-events/2023-fall-members-meeting/
LOCATION:The St. Anthony Hotel\, San Antonio\, 300 East Travis Street\, San Antonio\, TX\, 78205\, United States
CATEGORIES:Members Only
ORGANIZER;CN="Jeff Blake":MAILTO:jeff@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T130000
DTEND;TZID=America/New_York:20231012T140000
DTSTAMP:20260406T063156
CREATED:20230919T202008Z
LAST-MODIFIED:20230919T202008Z
UID:45606-1697115600-1697119200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview from Novo Nordisk - A Label Update on Rebinyn\, (Coagulation Factor IX (Recombinant)\, GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B
DESCRIPTION:Date: Thursday\, October 12\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nA Label Update on Rebinyn\, (Coagulation Factor IX (Recombinant)\, GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B \nOBJECTIVE:\nProvide a clinical review of Rebinyn that supports prophylaxis\, on-demand and perioperative indication in adults and children \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nParin Chikani\, PharmD\, MBA \nMedical Account Director\, Novo Nordisk Inc \nParin Chikani\, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago\, College of Pharmacy and his MBA from Kellstadt Graduate School of Business.  Before joining Novo Nordisk\, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business.  At Novo Nordisk\, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-from-novo-nordisk-a-label-update-on-rebinyn/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231024T140000
DTEND;TZID=America/New_York:20231024T150000
DTSTAMP:20260406T063156
CREATED:20231003T184948Z
LAST-MODIFIED:20231005T175043Z
UID:45701-1698156000-1698159600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa\, A High Sustained Factor VIII Therapy
DESCRIPTION:Date: Tuesday\, October 24\, 2023\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nA Clinical Overview and Update from Sanofi for Efanesoctocog Alfa\, A High Sustained Factor VIII Therapy \nOBJECTIVES: \n\nHighlighting both Efanesoctocog Alfa’s pediatric study\, the XTEND-Kids data that were presented at ISTH 2023\, as well as an observational study of patients who switched from current therapy to Efanesoctocog Alfa prophylaxis.\nHighlighting available lab monitoring program available to your centers.\n\nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nNancy Epp\, PharmD\, BCACP \nNancy Epp is a Senior Medical Science Liaison with Sanofi. She supports the Sanofi hemophilia A and B portfolio to provide up-to-date scientific data to healthcare providers. Nancy is based in Houston\, Texas\, and can be reached by email at Nancy.Epp@sanofi.com.
URL:https://hemoalliance.org/alliance-events/a-clinical-overview-and-update-from-sanofi-for-efanesoctocog-alfa-a-high-sustained-factor-viii-therapy/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR